Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kyttaris, V C
Right arrow Articles by Tsokos, G C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kyttaris, V C
Right arrow Articles by Tsokos, G C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 15, No. 12, 840-844 (2006)
DOI: 10.1177/0961203306069985

cAMP response element modulator {alpha} expression in patients with systemic lupus erythematosus

V C Kyttaris

Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA, Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD, USA, Section of Rheumatology, Washington Hospital Center, Washington, DC, USA

Y Wang

Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA

Y-T Juang

Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA, Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD, USA

A Weinstein

Section of Rheumatology, Washington Hospital Center, Washington, DC, USA

G C Tsokos

Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, MD, USA, Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD, USA, gtsokos{at}gmail.com

T cells from patients with systemic lupus erythematosus (SLE) have high levels of cAMP response element modulator (CREM)-{alpha} which bind to the interleukin (IL-2) promoter and limit IL-2 production. In this case-controlled study, we show that CREM-{alpha} mRNA levels were higher in T cells from patients with SLE than controls while CREB mRNA levels did not differ between the two groups. CREM-{alpha} mRNA levels did not correlate with clinical characteristics, disease activity or treatment. Nevertheless, there was a trend for patients on high doses of corticosteroids to have low levels of CREM-{alpha} mRNA. The discovery of specific non-toxic medications that block the expression of CREM-{alpha} may prove useful in reversing the aberrant T cell function in SLE.

Key Words: corticosteroids • CREM • lupus • T cells • transcription factors

References

  • Tsokos GC, Nambiar MP, Tenbrock K, Juang YT. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE . Trends Immunol 2003; 24: 259-263 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Linker-Israeli M, Bakke AC, Kitridou RCet al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE) . J Immunol 1983; 130: 2651-2655 .[Abstract]
  • Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus . Semin Arthritis Rheum 1996; 25: 318-318 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2 . Nat Rev Immunol 2004; 4: 665-674 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus . Scand J Immunol 2004; 59: 198-202 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Tsokos GC, Kammer GM. Molecular aberrations in human systemic lupus erythematosus . Mol Med Today 2000; 6: 418-418 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Tsokos GC, Boumpas DT. Systemic lupus erythematosus. In Molecular pathology of autoimmunity. Gordon and Breach, Harwood Academic Publishers , 2001; 255-255.
  • Jain J, Loh C, Rao A. Transcriptional regulation of the IL-2 gene . Curr Opin Immunol 1995; 7: 333-342 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus . J Immunol 2001; 166: 4216-4222 .[Abstract/Free Full Text]
  • Kyttaris VC, Juang YT, Tenbrock K, Weinstein A, Tsokos GC. Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus . J Immunol 2004; 173: 3557-3563 .[Abstract/Free Full Text]
  • Hochberg M. Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1725-1725 .[ISI][Medline] [Order article via Infotrieve]
  • Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI . Arthritis Rheum 1992; 6: 630-630 .
  • Bustin SA. Absolute quantification using real-time reverse transcription polymerasechain reaction assays . J Molecular Endocrinology 2000; 25: 169-193 .
  • Vacca A, Felli MP, Farina ARet al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements . J Exp Med 1992; 175: 637-646 .[Abstract/Free Full Text]
  • Juang YT, Wang Y, Solomou EEet al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV . J Clin Invest 2005; 115: 996-1005 .[CrossRef][ISI][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kyttaris, V C
Right arrow Articles by Tsokos, G C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kyttaris, V C
Right arrow Articles by Tsokos, G C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?